

## Joslin Diabetes FOCUS™

A satellite-delivered continuing medical education broadcast series targeting issues related to the care of people with diabetes and its complications.

*Announces a video presentation:*

## SCHIZOPHRENIA, BIPOLAR DISORDERS, & DIABETES: INTERRELATIONSHIPS AND INTERVENTIONS

**TUESDAY, SEPTEMBER 16, 2003**

12:30 PM - 1:30 PM ET

1:30 PM - 2:30 PM ET

3:30 PM - 4:30 PM ET

### MODERATOR

**Richard S. Beaser, MD**

Assistant Clinical Professor of Medicine

Harvard Medical School

Executive Director, Continuing Medical Education

Joslin Diabetes Center

Boston, MA

### FACULTY

**Philip Levy, MD**

Clinical Professor of Medicine

University of Arizona College of Medicine

Tucson, AZ

**John W. Newcomer, MD**

Associate Professor of Psychiatry

Washington University School of Medicine

St. Louis, MO

**To register your site or for more information, please contact IMN at 888.466.3250. Thank you.**

### STATEMENT OF NEED

It has been documented that patients with schizophrenia and bipolar disorders may be at greater than average risk for the metabolic syndrome and the resulting conditions of diabetes, hypertension, lipid disorders, and coronary artery disease. While lifestyle choices and genetics play a role in this increased risk, evidence has suggested an association between some second-generation antipsychotic agents and obesity and/or related metabolic changes. While most mental health professionals are not officially primary care clinicians, they are often in the best position to recognize early signs and symptoms of metabolic abnormalities, and are in a position to initiate treatment or at least refer patients for intervention should signs or symptoms be detected. Further, as they oversee antipsychotic treatments, they may balance psychiatric treatment needs with the potential for metabolic impact in therapeutic design decisions.

The activity content will address recent scientific data concerning patients with schizophrenia and other psychotic disorders such as bipolar disorders. It will also address the growing literature that explores the relationship between the common treatments for these psychiatric illnesses and physiologic changes that result in an increased incidence of metabolic disorders such as diabetes and cardiac rhythm disturbances. The activity will empower mental health professionals to choose medications with consideration of the potential for metabolic risk, and to initiate treatment or refer for intervention when the clinical signs of the metabolic syndrome and diabetes are detected in patients with schizophrenia and bipolar disorders.

### LEARNING OBJECTIVES

Participants will be provided with evidence-based practical and clinically relevant information. At the completion of this activity (EDA 556-0033), the participant should be able to:

- Recognize the signs and symptoms of the metabolic syndrome in people with schizophrenia and bipolar disorders, whether or not related to its treatments
- Apply knowledge of the pharmacology of antipsychotic medications to more effectively utilize these treatment tools in people with schizophrenia and bipolar disorders
- Describe the interrelationships between conditions and treatments of schizophrenia, bipolar disorders, and the metabolic syndrome
- Select antipsychotic treatments that balance psychiatric treatment impact, macrovascular risk considerations, and the potential for development of the metabolic syndrome
- Initiate preventive and/or therapeutic interventions, or seek consultative assistance to do so, when manifestations of diabetes or other components of the insulin resistance syndrome or metabolic syndrome are present

### TARGET AUDIENCE

This accredited activity has been developed for psychiatrists, psychiatric nurses, pharmacists, and other clinicians who treat patients with severe psychiatric conditions.

### ACCREDITATION AND DESIGNATION OF CREDIT

In the interest of full disclosure, please be advised that pharmaceutical supporters may obtain lists of registrants for internal assessment of the efficacy of the activity.

The Joslin Diabetes Center, Boston, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. The Joslin Diabetes Center designates this educational activity for a maximum of 1.0 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. This CME activity was planned and produced in accordance with ACCME Essentials.

Joslin Diabetes Center adheres to ACCME Essential Areas, Policies, and Standards for Commercial Support regarding industry support of continuing medical education. Disclosure of faculty's commercial relationships will be made known in the program handout materials and at the beginning of the broadcast. Speakers are expected to disclose any discussion of unlabeled or investigational uses of products that are mentioned in their presentations.

This activity for 1.2 contact hours is provided by PRIMEDIA Healthcare, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.



PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, is accredited by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

**CE Credit:** 1.0 Contact Hour(s), or 0.10 CEU(s) **Universal Program Number:** 775-999-03-034-H01

Successful completion of this activity includes the following:

- View the satellite broadcast or videotape and review the syllabus.
- Complete the appropriate CE application and evaluation form. Excluding physicians, participants must complete the posttest.
- Submit the forms to the Site Coordinator or address indicated for processing.

Participants will receive a Certificate/Statement of Credit within 4 weeks following receipt of the CME/CE application and evaluation form.

**There is no fee for participation in this activity.**

Viewing information at this site: Date: \_\_\_\_\_ Time(s): \_\_\_\_\_  
Location: \_\_\_\_\_



A division  
of  
PRIMEDIA  
Healthcare

INTERACTIVE MEDICAL NETWORKS

**THE GOLD STANDARD IN CME**

**This activity is supported by an unrestricted  
educational grant from Pfizer Inc.**